Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Pyrosequencing Teams With Hospital to Develop Diagnostics

NEW YORK, June 18 - In another move towards entering the diagnostics market, Pyrosequencing said Monday it had signed a research agreement with The Children's Hospital of Philadelphia to analyze genes associated with deafness. 

Pyrosequencing, of Uppsala, Sweden, which initially positioned its sequencing technology to exploit the research market, has said repeatedly that it is hoping to develop diagnostic products. Last month, the company said it had been awarded a patent for applying its technology to assessing cardiovascular conditions such as myocardial infarction and stroke.

The agreement with The Children's Hospital of Philadelphia (CHOP) will target the Connexin 26 gene, a gene with mutations associated with 65 percent of autosomal recessive non-syndromic hearing loss. Researchers at the Molecular Diagnostics Laboratory at CHOP will use Pyrosequencing's sequencing technology to screen patients with this type of deafness to analyze mutations in the Connexin 26 gene. 

The team at CHOP will also screen patients for a genetic mutation associated with hearing loss in children treated with aminoglyside antibiotics, the company said. 

Erik Wallden, CEO of Pyrosequencing, told GenomeWeb that he hopes to find other academic partners to help validate the potential of his company's technology as a diagnostic tool. Pyrosequencing's technology has a "set of features attractive for diagnostics," he said, "but it has to be validated and that why we're collaborating."

Pyrosequencing has a US-based business development team that is actively searching out opportunities to develop diagnostic tools, Wallden said, so it's "reasonable to expect more of these types of collaborations," he said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.